<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2312-3893</journal-id>
<journal-title><![CDATA[Revista Virtual de la Sociedad Paraguaya de Medicina Interna]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. virtual Soc. Parag. Med. Int.]]></abbrev-journal-title>
<issn>2312-3893</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Paraguaya de Medicina Interna]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2312-38932024000100011</article-id>
<article-id pub-id-type="doi">10.18004/rvspmi/2312-3893/2024.e11122413</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Monoterapia versus terapia combinada como tratamiento de infecciones por Acinetobacter baumannii multirresistente]]></article-title>
<article-title xml:lang="en"><![CDATA[Monotherapy versus combination therapy as treatment of multidrug-resistant Acinetobacter baumannii infections]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Caballero Torres]]></surname>
<given-names><![CDATA[Marlene Elizabeth]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Alvarenga Tanii]]></surname>
<given-names><![CDATA[Amy Fabiola]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Bruno Aquino]]></surname>
<given-names><![CDATA[Freddy Javier]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cáceres Santacruz]]></surname>
<given-names><![CDATA[Sandra Manuela]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ocampos Mamani]]></surname>
<given-names><![CDATA[Cinthia Carolina]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Servín Espinoza]]></surname>
<given-names><![CDATA[Patricia Victoria]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Zaputovich Filippi]]></surname>
<given-names><![CDATA[Juan José]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Ministerio de Salud Pública y Bienestar Social Centro Médico Nacional Hospital Nacional]]></institution>
<addr-line><![CDATA[Itauguá ]]></addr-line>
<country>Paraguay</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2024</year>
</pub-date>
<volume>11</volume>
<numero>1</numero>
<fpage>11</fpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.iics.una.py/scielo.php?script=sci_arttext&amp;pid=S2312-38932024000100011&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.iics.una.py/scielo.php?script=sci_abstract&amp;pid=S2312-38932024000100011&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.iics.una.py/scielo.php?script=sci_pdf&amp;pid=S2312-38932024000100011&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción: Acinetobacter baumannii se asocia a una alta morbimortalidad, una mayor estancia hospitalaria y, por lo tanto, un gran impacto sanitario.  Objetivos:  comparar la respuesta clínica y la supervivencia empleando como tratamiento antibiótico colistina endovenosa frente a colistina combinada con altas dosis de ampicilina/sulbactam ante infecciones por A. baumannii multirresistente en las salas de cuidados intensivos de adultos del Hospital Nacional (Itauguá, Paraguay)  Materiales y métodos:  se aplicó un diseño de cohortes retrospectivas donde se analizó la respuesta clínica y laboratorial, la supervivencia a los 14 días y la tasa de mortalidad en pacientes tratados con colistina 5 mg/kg/día como monoterapia frente a terapia combinada de colistina 5 mg/kg/día más ampicilina/sulbactam 9 gramos cuatro veces al día. Las variables se obtuvieron de los expedientes clínicos de pacientes &#8805;18 años infectados con A. baumannii multirresistente.  Resultados:  se incluyeron 163 pacientes, con edad media de 50 ± 17 años, siendo el 61,96% de sexo masculino. El 69,33% presentó neumonía asociada a ventilación mecánica, el 21,47% bacteriemia, el 5,52% ventriculitis y el 3,68% infección relacionada a vía venosa central. Una cohorte de 88 pacientes recibió monoterapia con colistina endovenosa y otra de 75 pacientes la terapia combinada de colistina endovenosa más dosis altas de ampicilina/sulbactam. No se encontró diferencias en la puntuación de APACHE II entre ambas cohortes. La cohorte con tratamiento combinado demostró superioridad estadísticamente significativa al presentar mejoría clínica y laboratorial a las 72 hs, menor necesidad de vasopresores, mejor sobrevida a los 14 días y menor nefrotoxicidad. La tasa de mortalidad global fue del 45,40%.  Conclusión:  la terapia combinada de colistina endovenosa con dosis altas de ampicilina/sulbactam en infusión prolongada se encontró relacionada a mejoría clínica temprana, menor tiempo de requerimiento de vasopresores y asistencia respiratoria mecánica, mayor supervivencia a los 14 días y menor nefrotoxicidad.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction: Acinetobacter baumannii is associated with high morbidity and mortality, longer hospital stays, and, therefore, a great health impact.  Objectives: To compare the clinical response and survival using intravenous colistin as antibiotic treatment versus colistin combined with high doses of ampicillin/sulbactam in multidrug-resistant A. baumannii infections in the adult intensive care units of the National Hospital (Itauguá, Paraguay).  Materials and methods:  A retrospective cohort design was applied to analyze the clinical and laboratory response, 14-day survival, and mortality rate in patients treated with colistin five mg/kg/day as monotherapy versus combined colistin therapy five mg/kg/day plus ampicillin/sulbactam 9 grams four times a day. The variables were obtained from the clinical records of patients &#8805;18 years old infected with multidrug-resistant A. baumannii.  Results:  One hundred sixty-three patients were included, with a mean age of 50 ± 17 years, 61.96% male. Pneumonia associated with mechanical ventilation was present in 69.33%, bacteremia in 21.47%, ventriculitis in 5.52% and infections related to the central venous line in 3.68%. A cohort of 88 patients received monotherapy with intravenous colistin and another of 75 patients received combined therapy with intravenous colistin plus high doses of ampicillin/sulbactam. No differences were found in the APACHE II score between both cohorts. The cohort with combined treatment demonstrated statistically significant superiority by presenting clinical and laboratory improvement at 72 hours, less need for vasopressors, better survival at 14 days, and less nephrotoxicity. The overall mortality rate was 45.40%.  Conclusion:  The combined therapy of intravenous colistin with high doses of ampicillin/sulbactam in prolonged infusion was related to early clinical improvement, shorter time requiring vasopressors and mechanical ventilation, greater survival at 14 days, and less nephrotoxicity.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Acinetobacter baumannii]]></kwd>
<kwd lng="es"><![CDATA[colistina]]></kwd>
<kwd lng="es"><![CDATA[ampicilina]]></kwd>
<kwd lng="es"><![CDATA[sulbactam]]></kwd>
<kwd lng="es"><![CDATA[farmacorresistencia bacteriana]]></kwd>
<kwd lng="en"><![CDATA[Acinetobacter baumannii]]></kwd>
<kwd lng="en"><![CDATA[colistin]]></kwd>
<kwd lng="en"><![CDATA[ampicillin]]></kwd>
<kwd lng="en"><![CDATA[sulbactam]]></kwd>
<kwd lng="en"><![CDATA[bacterial drug resistance]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lasheen]]></surname>
<given-names><![CDATA[AF]]></given-names>
</name>
<name>
<surname><![CDATA[As]]></surname>
<given-names><![CDATA[Sleem]]></given-names>
</name>
<name>
<surname><![CDATA[Elmahdy]]></surname>
<given-names><![CDATA[EES]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Multi-drug resistance profile of virulent biofilm forming acinetobacter baumanii isolates in Intensive Care Units]]></article-title>
<source><![CDATA[Egypt J Med Microbiol]]></source>
<year>2023</year>
<volume>32</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>105-11</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[ChJL]]></surname>
<given-names><![CDATA[Murray]]></given-names>
</name>
<name>
<surname><![CDATA[Ikuta]]></surname>
<given-names><![CDATA[KS]]></given-names>
</name>
<name>
<surname><![CDATA[Sharara]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Swetschinski]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Robles Aguilar]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Gray]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2022</year>
<volume>399</volume>
<numero>10325</numero>
<issue>10325</issue>
<page-range>629-55</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shields]]></surname>
<given-names><![CDATA[RK]]></given-names>
</name>
<name>
<surname><![CDATA[Paterson]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
<name>
<surname><![CDATA[Tamma]]></surname>
<given-names><![CDATA[PD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Navigating available treatment options for carbapenem-resistant acinetobacter baumannii-calcoaceticus complex infections]]></article-title>
<source><![CDATA[Clin Infect Dis]]></source>
<year>2023</year>
<volume>76</volume>
<numero>Suppl 2</numero>
<issue>Suppl 2</issue>
<page-range>S179-93</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jung]]></surname>
<given-names><![CDATA[SY]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[SY]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Noh]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Chung]]></surname>
<given-names><![CDATA[EK]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[JI]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antimicrobials for the treatment of drug-resistant Acinetobacter baumannii pneumonia in critically ill patients]]></article-title>
<source><![CDATA[Crit Care]]></source>
<year>2017</year>
<volume>21</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>319</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Shu]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Zhu]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Feng]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparative efficacy and safety of combination therapy with high-dose sulbactam or colistin with additional antibacterial agents for multiple drug-resistant and extensively drug-resistant Acinetobacter baumannii infections]]></article-title>
<source><![CDATA[J Glob Antimicrob Resist]]></source>
<year>2021</year>
<volume>24</volume>
<page-range>136-47</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Seanglaw]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Morasert]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Development of a prediction model for acute kidney injury after colistin treatment for multidrug-resistant acinetobacter baumanii ventilator-associated pneumonia]]></article-title>
<source><![CDATA[J Health Sci Med Res]]></source>
<year>2023</year>
<volume>41</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Reina]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[León-Moya]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Garnacho-Montero]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment of acinetobacter baumannii severe infections]]></article-title>
<source><![CDATA[Med Intensiva]]></source>
<year>2022</year>
<volume>46</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>700-10</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lopez-Cortes]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
<name>
<surname><![CDATA[Cisneros]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Fernandez-Cuenca]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Bou]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Tomas]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Garnacho-Montero]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Monotherapy versus combination therapy for sepsis due to multidrug-resistant Acinetobacter baumannii]]></article-title>
<source><![CDATA[J Antimicrob Chemother]]></source>
<year>2014</year>
<volume>69</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>3119-26</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sultana]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Shamsuzzaman]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Yusuf]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Asifudduza]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rahman]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Begum]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Jahan]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Biofilm formation and its association with antimicrobial resistance among clinical isolates of acinetobacter baumanii at a Tertiary Care Hospital in Dhaka City of Bangladesh]]></article-title>
<source><![CDATA[Bangladesh J Infect Dis]]></source>
<year>2022</year>
<volume>8</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>82-6</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vázquez-López]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Solano-Gálvez]]></surname>
<given-names><![CDATA[SG]]></given-names>
</name>
<name>
<surname><![CDATA[Juárez Vignon-Whaley]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Abello Vaamonde]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Padró Alonzo]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Rivera Reséndiz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Acinetobacter baumannii resistance: A real challenge for clinicians]]></article-title>
<source><![CDATA[Antibiotics]]></source>
<year>2020</year>
<volume>9</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>205</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Corona]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[De Santis]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Agarossi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Prete]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cattaneo]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Tomasini]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antibiotic Therapy Strategies for Treating Gram-Negative Severe Infections in the Critically Ill]]></article-title>
<source><![CDATA[Antibiotics]]></source>
<year>2023</year>
<volume>12</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1262</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tamma]]></surname>
<given-names><![CDATA[PD]]></given-names>
</name>
<name>
<surname><![CDATA[Aitken]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Bonomo]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Mathers]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[van Duin]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Clancy]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Infectious Diseases Society of America Guidance on the treatment of AmpC &#946;-Lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections]]></article-title>
<source><![CDATA[Clin infect Dis]]></source>
<year>2022</year>
<volume>74</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>2089-114</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Urrutia Gómez]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Rueda Riaño]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Rojas Páez]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Silva Rodríguez]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Méndez Faniño]]></surname>
<given-names><![CDATA[YR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Eficacia de la colisina en el tratamiento de pacientes adultos con infecciones severas por Acinetobacter baummannii XDR en cuidados intensivos]]></article-title>
<source><![CDATA[Univ Méd]]></source>
<year>2016</year>
<volume>57</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>212-25</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ramírez-Palomino]]></surname>
<given-names><![CDATA[VA]]></given-names>
</name>
<name>
<surname><![CDATA[Saal-Zapata]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tratamiento exitoso de la ventriculitis por Acinetobacter baumanii multidrogo resistente con colistina intravenosa e intraventricular]]></article-title>
<source><![CDATA[Rev Med Hered]]></source>
<year>2021</year>
<volume>32</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>46-50</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Batirel]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Balkan]]></surname>
<given-names><![CDATA[II]]></given-names>
</name>
<name>
<surname><![CDATA[Karabay]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Agalar]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Akalin]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Alici]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections]]></article-title>
<source><![CDATA[Eur J Clin Microbiol Infect Dis]]></source>
<year>2014</year>
<volume>33</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1311-22</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Makris]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Petinaki]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Tsolaki]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Manoulakas]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Mantzarlis]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Apostolopoulou]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Colistin versus Colistin Combined with Ampicillin- Sulbactam for multiresistant acinetobacter baumannii ventilator-associated pneumonia treatment: An open-label prospective study]]></article-title>
<source><![CDATA[Indian J Crit Care Med]]></source>
<year>2018</year>
<volume>22</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>67-77</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kengkla]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Kongpakwattana]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Saokaew]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Apisarnthanarak]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Chaiyakunapruk]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter baumannii infections]]></article-title>
<source><![CDATA[J Antimicrob Chemother]]></source>
<year>2018</year>
<volume>73</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>22-32</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barletta Farías]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez Ponce]]></surname>
<given-names><![CDATA[LJ]]></given-names>
</name>
<name>
<surname><![CDATA[Castro Vega]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Pujol Pérez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Barletta del Castillo]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Dueñas Pérez]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Acinetobacter baumannii multirresistente]]></article-title>
<source><![CDATA[Medisur]]></source>
<year>2018</year>
<volume>16</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>322-34</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
